These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33301908)

  • 61. Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?
    Janiaud P; Hemkens LG; Ioannidis JPA
    Can J Cardiol; 2021 Sep; 37(9):1353-1364. PubMed ID: 34077789
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Does the COVID-19 war metaphor influence reasoning?
    Panzeri F; Di Paola S; Domaneschi F
    PLoS One; 2021; 16(4):e0250651. PubMed ID: 33909699
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aid agencies escalate Gaza relief effort.
    Zarocostas J
    Lancet; 2021 Jun; 397(10290):2136. PubMed ID: 34090595
    [No Abstract]   [Full Text] [Related]  

  • 64. COVID-19 pandemic is not the time of trial and error.
    Mohamed K; Rezaei N
    Am J Emerg Med; 2021 Aug; 46():774-775. PubMed ID: 32988694
    [No Abstract]   [Full Text] [Related]  

  • 65. Of chloroquine and COVID-19.
    Touret F; de Lamballerie X
    Antiviral Res; 2020 May; 177():104762. PubMed ID: 32147496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. COVID-19 Ethics and Research.
    Meagher KM; Cummins NW; Bharucha AE; Badley AD; Chlan LL; Wright RS
    Mayo Clin Proc; 2020 Jun; 95(6):1119-1123. PubMed ID: 32402511
    [No Abstract]   [Full Text] [Related]  

  • 67. Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
    Viale G; Licata L; Sica L; Zambelli S; Zucchinelli P; Rognone A; Aldrighetti D; Di Micco R; Zuber V; Pasetti M; Di Muzio N; Rodighiero M; Panizza P; Sassi I; Petrella G; Cascinu S; Gentilini OD; Bianchini G
    Oncologist; 2020 Jul; 25(7):e1013-e1020. PubMed ID: 32412693
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.
    Piantadosi S
    Clin Trials; 2020 Oct; 17(5):483-490. PubMed ID: 32666816
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is it ethically appropriate to continue surgical clinical trials during the COVID-19 pandemic?
    Milner R; Donington J; Matthews JB; Posner M; Turaga K; Angelos P
    Surgery; 2020 Jul; 168(1):1-3. PubMed ID: 32482342
    [No Abstract]   [Full Text] [Related]  

  • 70. US Food and Drug Administration Support for Oncology Drug Development During COVID-19.
    Kadakia KT; Pazdur R; Shah A
    JAMA Oncol; 2021 Jan; 7(1):27-28. PubMed ID: 33030504
    [No Abstract]   [Full Text] [Related]  

  • 71. Modifications to Communities for Healthy Living trial design resulting from COVID-19.
    Davison KK; Haneuse S
    Contemp Clin Trials; 2020 Dec; 99():106205. PubMed ID: 33152514
    [No Abstract]   [Full Text] [Related]  

  • 72. Impact of COVID-19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective.
    Mohamed MF; Girish S; Humeniuk R; Nuthalapati S; Desai A; Datta-Mannan A; Gheyas F; Kanodia J; Cheeti S; Zhu T
    Clin Pharmacol Ther; 2024 Jul; 116(1):26-29. PubMed ID: 38536001
    [No Abstract]   [Full Text] [Related]  

  • 73. The qualitative method for a humanisation of research.
    Artioli G; Sarli L
    Acta Biomed; 2021 Jul; 92(S2):e2021041. PubMed ID: 34328126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical trial design during and beyond the pandemic: the I-SPY COVID trial.
    I-SPY COVID Consortium
    Nat Med; 2022 Jan; 28(1):9-11. PubMed ID: 35058620
    [No Abstract]   [Full Text] [Related]  

  • 75. Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in France.
    Raimond V; Mousquès J; Avorn J; Kesselheim AS
    J Law Med Ethics; 2021; 49(1):139-151. PubMed ID: 33966651
    [TBL] [Abstract][Full Text] [Related]  

  • 76. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape.
    Mullard A
    Nat Rev Drug Discov; 2021 May; 20(5):336-337. PubMed ID: 33864035
    [No Abstract]   [Full Text] [Related]  

  • 77. Routine workflow in a reference clinical research center in face of COVID-19.
    Cardoso ASF; Silva SMR; Rabelo-Silva ER; Umpierre D; Sostizzo LDRZ; Echer IC
    Rev Gaucha Enferm; 2021; 42(spe):e20200389. PubMed ID: 34586333
    [TBL] [Abstract][Full Text] [Related]  

  • 78. How COVID broke the evidence pipeline.
    Pearson H
    Nature; 2021 May; 593(7858):182-185. PubMed ID: 33981057
    [No Abstract]   [Full Text] [Related]  

  • 79. Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination.
    Lansky A; Shah T; Wijns W; Stefanini GG; Farb A; Kaplan A; Xu B; Pietras C; Velazquez E; Serruys PW; Mahfoud F; Baumbach A
    EuroIntervention; 2020 Nov; 16(10):787-793. PubMed ID: 33215993
    [No Abstract]   [Full Text] [Related]  

  • 80. Not What Anyone Signed up for: Unnecessary and Insurmountable Barriers Encountered in Conducting Clinical Trials in COVID-19.
    Branch-Elliman W; Monach PA
    Narrat Inq Bioeth; 2021; 11(1):8-15. PubMed ID: 34334456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.